Scandinavian Cardiovascular Journal最新文献

{"title":"Shrunken pore syndrome in heart transplantation: a pore ready to close?","authors":"Erik Herou, Emilie Mörtsell, Anders Grubb, Shahab Nozohoor, Igor Zindovic, Per Ederoth, Alain Dardashti, Henrik Bjursten","doi":"10.1080/14017431.2025.2481173","DOIUrl":"10.1080/14017431.2025.2481173","url":null,"abstract":"<p><p><i>Background</i>: A newly discovered renal syndrome, shrunken pore syndrome (SPS), has been shown to increase mortality regardless of renal function. SPS is defined as an estimated glomerular filtration rate (eGFR) of cystatin C ≤ 60% than eGFR_creatinine. We set out to study SPS in relation to the survival of heart transplantation patients with a follow-up of up to 12 years. <i>Methods.</i> This was a single-center cohort study including 253 consecutive patients undergoing heart transplantation. The prevalence of SPS at different time points post-transplantation and its effect on survival was evaluated using Kaplan-Meier's analysis and multivariable Cox proportional hazards regression. <i>Results.</i> The prevalence of SPS was 7.5% the day after transplantation (D1), which rose to 71% week 4 after surgery. There was no difference in survival for patients with SPS D1 compared to patients without SPS D1. Patients with SPS 4 weeks compared to patients without SPS 4 weeks after transplantation showed a 5- and 10-year survival of 73% vs. 93% (<i>p</i> = .02) and 63% vs. 90% (<i>p</i> = .005), respectively. SPS developed during the postoperative period was also found to be an independent predictor of mortality (HR 4.65; 95% CI 1.36-15.8). <i>Discussion.</i> SPS that developed in the postoperative course after heart transplantation was found to be an independent predictor of mortality with a severe negative impact on 5- and 10-year survival.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":" ","pages":"2481173"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of permanent pacemaker implantation after transcatheter aortic valve implantation.","authors":"Martin Petter Høydahl, Didrik Kjønås, Assami Rösner, Bendik Trones Antonsen, Signe Helene Forsdahl, Rolf Busund","doi":"10.1080/14017431.2025.2481175","DOIUrl":"10.1080/14017431.2025.2481175","url":null,"abstract":"<p><p><i>Purpose</i>. Transcatheter aortic valve implantation (TAVI) is increasingly performed in patients with longer life expectancies. The need for permanent pacemaker implantation (PPI) following TAVI has been associated with increased all-cause mortality and morbidity. This study aimed to identify ECG, CT, and procedural predictors of PPI following TAVI. <i>Methods.</i> We conducted a retrospective observational study at the University Hospital of North Norway. Patients who underwent TAVI with SAPIEN 3 or SAPIEN 3 Ultra valves were included, while those with prior pacemakers, self-expanding valves, or valve-in-valve procedures were excluded. Data were collected from medical records, pre-operative CT scans, and procedural angiography. <i>Results.</i> A total of 416 low- to intermediate-risk patients with a median age of 82 years were included. Of these, 64 patients (15.4%) required PPI within ≤30 days following the index procedure. Multivariable regression analysis identified the following predictors for PPI: pre-existing right bundle branch block (odds ratio (OR), 10.7; 95% CI, 4.74-24.3), first-degree atrioventricular block (OR, 2.62; 95% CI, 1.08-6.32), membranous septum length (OR, 0.77; 95% CI, 0.65-0.90), left ventricular outflow tract calcification (OR, 2.18; 95% CI, 1.12-4.27), and the use of 29 mm valves (OR, 2.33; 95% CI, 1.09-4.97). <i>Conclusions.</i> Our study found the following predictors of PPI following TAVI: pre-existing right bundle branch block, first-degree atrioventricular block, the use of 29 mm valves and the presence of left ventricular outflow tract calcification. Additionally, a short MS was found to increase the chance of PPI; therefore, MS measurements should be included in pre-operative assessments to identify at-risk patients.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":" ","pages":"2481175"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity levels and associated biopsychosocial characteristics among attendees to exercise-based cardiac rehabilitation.","authors":"Hedvig Zetterberg, Annika Bring, Emil Hagström, Marie Breidenskog, Henrik Johansson, Charlotte Urell","doi":"10.1080/14017431.2025.2472763","DOIUrl":"10.1080/14017431.2025.2472763","url":null,"abstract":"<p><p><i>Aim</i>. Exercise-based cardiac rehabilitation (exCR) reduces morbidity and mortality after acute coronary syndrome (ACS). Little is known about physical activity (PA) levels at exCR program completion and associated demographic, medical, and psychosocial factors. <i>Methods</i>. Cross-sectional data from the ongoing Keep-Up-Going study were used, including 100 participants with recent ACS and ≥80% attendance to 3 months supervised exCR program. Physical activity was assessed by an accelerometer and self-reported psychosocial characteristics were collected at the end of the exCR. Associations between achieving the PA target (>150 min of moderate-to-vigorous-intensity PA/week) and biopsychosocial characteristics were assessed using univariable logistic regression analyses. <i>Results</i>. Mean age was 67 years and 24% were women. Participants achieving the PA target (76%) were more likely to have higher levels of social support, higher outcome expectations for PA, and higher intrinsic regulation (motivation, <i>p</i> < .05 for all). Those not achieving the PA target (24%) had a higher proportion of sedentary time, fewer steps/day, and were more likely to be older, retired, and have reduced left ventricular ejection fraction (LVEF) (<i>p</i> < .05 for all). <i>Conclusions</i>. Although exCR participation provides exercise routines, one-fourth of individuals did not reach the guideline-directed PA targets after an ACS. In addition to higher age and reduced LVEF, lower levels of social support, outcome expectations, and motivation were associated with low levels of PA. Exploring these factors could be of importance to support individuals' behavior change toward increased PA during the exCR period.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":" ","pages":"2472763"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vasomotor and fibrinolytic effects of leptin in man.","authors":"Manuel Gonzalez, Simon Robinson, Nicholas L Mills, Marie Eriksson, Thomas Sandström, David E Newby, Tommy Olsson, Anders Blomberg, Stefan Söderberg","doi":"10.1080/14017431.2025.2478867","DOIUrl":"10.1080/14017431.2025.2478867","url":null,"abstract":"<p><strong>Objectives: </strong>The adipocyte-derived hormone leptin has been associated with the pathogenesis of cardiovascular disease. The mechanisms underlying this association are unclear but may relate to effects on the vascular endothelium. Our aim was to explore the effects of leptin on endothelial vasomotor and fibrinolytic function in healthy volunteers and patients with coronary artery disease.</p><p><strong>Design: </strong>The vascular effects of leptin were assessed infusing recombinant human leptin in healthy volunteers during measuring vasomotor response by venous occlusion plethysmography. Additionally, circulating levels of leptin were analysed in relation to endothelial dysfunction in patients with established coronary artery disease.</p><p><strong>Results: </strong>In healthy male volunteers, intra-arterial infusion of recombinant human leptin (80, 800 and 8,000 ng/min; <i>n</i> = 10) did not affect basal forearm blood flow, plasma tissue plasminogen activator (tPA) or plasminogen activator inhibitor type 1 concentrations (all <i>p</i> > 0.05). However, during concomitant co-infusion with leptin (800 ng/min; <i>n</i> = 10), drug-induced vasodilatation was reduced (<i>p</i> = 0.001), and tPA activity increased (<i>p</i> = 0.002). In patients with coronary artery disease, those with the high plasma leptin levels had reduced drug-induced vasodilatation (<i>p</i> < 0.001), and increased net release of tPA antigen and activity (<i>p</i> < 0.001 and <i>p</i> = 0.03, respectively) compared to those with low levels. The study has been registered retrospectively at Clinical Trials with number <b>NCT04374500.</b></p><p><strong>Conclusion: </strong>Intrabrachial leptin infusion did not affect the basal vascular tone, whereas acute and chronic hyperleptinemia was associated with blunted vasoreactivity in healthy volunteers, and in patients with coronary artery disease.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":" ","pages":"2478867"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of antiarrhythmic drugs for atrial fibrillation in Finland 2007-2018.","authors":"Rasmus Siponen, Juha Hartikainen, Janne Virrankorpi, Antti Lappalainen, Konsta Teppo, Olli Halminen, Aapo Aro, Annukka Marjamaa, Birgitta Salmela, Jari Haukka, Jukka Putaala, Miika Linna, Pirjo Mustonen, Juhani Airaksinen, Mika Lehto","doi":"10.1080/14017431.2025.2467735","DOIUrl":"10.1080/14017431.2025.2467735","url":null,"abstract":"<p><strong>Background: </strong>Patients with atrial fibrillation (AF) are often treated with antiarrhythmic drugs (AADs) to maintain sinus rhythm and with heart rate-lowering drugs to achieve the optimal rate control. In this study, we investigated trends in the use of AADs and rate control drugs in Finnish patients with AF.</p><p><strong>Methods and results: </strong>The Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) study is a nationwide study including all patients with AF in Finland from 2007 to 2018. The number of AAD purchases and the proportions of all prevalent AF patients in a certain year of interest were calculated. In total, 391030 AF patients were identified between 2007 and 2018, and 39,816 (10.2%) of them had purchased either class I or III AADs. The proportion of patients using classes I and III AADs decreased from 8.6% to 6.3%. Flecainide and amiodarone were the most often used AADs. The use of flecainide and amiodarone decreased from 4.9% to 3.9% and 1.9% to 1.5%, respectively. The proportion of patients on beta-blockers remained stable at 75%. Dronedarone became available in 2011 when it also was the most used (0.8% of patients), but the use decreased thereafter. The use of sotalol and digoxin decreased from 1.5% to 0.6% and 24.6% to 11.0% over the study period.</p><p><strong>Conclusion: </strong>The number of AAD purchases increased alongside with the increasing prevalence of AF, whereas the proportion of AF patients on classes I and III AADs and digoxin decreased between 2007 and 2018. Flecainide remained the most used AAD followed by amiodarone.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":" ","pages":"2467735"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CircFNDC3B inhibits vascular smooth muscle cells proliferation in abdominal aortic aneurysms by targeting the miR-1270/PDCD10 axis.","authors":"Baoping Deng, Jing Xu, Yue Wei, Jinfeng Zhang, Na Zeng, Yulan He, Qiaoli Zeng, Dehua Zou, Runmin Guo","doi":"10.1080/14017431.2024.2441114","DOIUrl":"10.1080/14017431.2024.2441114","url":null,"abstract":"<p><p><i>Objectives</i>. This study investigated the role and underlying regulatory mechanisms of circular RNA fibronectin type III domain containing 3B (circFNDC3B) in abdominal aortic aneurysm (AAA). <i>Methods.</i> The expression of circFNDC3B in AAA and normal tissues was assessed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). To evaluate the biological functions of circFNDC3B, assays were employed including 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), flow cytometry, and Caspase-3 activity assays. Additionally, RNA immunoprecipitation (RIP), dual-luciferase reporter assay, Western blotting, and rescue experiments were utilized to elucidate the molecular mechanism of circFNDC3B. <i>Results.</i> Our findings revealed a significant upregulation of circFNDC3B expression in AAA clinical specimens compared to normal tissues. Functionally, overexpression of circFNDC3B inhibited vascular smooth muscle cells (VSMCs) proliferation and induced apoptosis, contributing to AAA formation in the Ang II-induced AAA model. Mechanistically, circFNDC3B acted as a molecular sponge for miR-1270, leading to the upregulation of programmed cell death 10 (PDCD10). Decreased expression of PDCD10 abrogated the -promoting effects of circFNDC3B overexpression on AAA development. <i>Conclusions.</i> This study demonstrates that circFNDC3B promotes the progression of AAA by targeting the miR-1270/PDCD10 pathway. Our findings suggest that circFNDC3B as well as miR-1270/PDCD10 pathway may serve as a potential therapeutic target for AAA treatment.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":" ","pages":"2441114"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multivariate and survival analysis of prognosis and surgical benefits in infective endocarditis.","authors":"Tian Xu Song, Yao Dong Sun, Bufan Zhang, Yu Xuan, Yi Ze Liu, Nai Shi Wu","doi":"10.1080/14017431.2024.2429994","DOIUrl":"10.1080/14017431.2024.2429994","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;i&gt;Background.&lt;/i&gt; Antibiotic therapy is the primary treatment for infective endocarditis (IE), yet up to 50% of patients still require surgical intervention. However, surgical intervention carries significant risks of mortality and complications for IE patients, and there remains a lack of consensus on which preoperative characteristics of infective endocarditis have a substantial impact on patient prognosis. Particularly, some IE patients develop periannular abscesses, leading to more severe complications. &lt;i&gt;Objectives.&lt;/i&gt; The objective of our study is to identify predictors of poor outcomes in infective endocarditis and to further evaluate the impact of surgical intervention on patient prognosis, with the aim of adding value to the existing factors known to affect IE prognosis. &lt;i&gt;Methods.&lt;/i&gt; In this retrospective cohort study, we evaluated 210 patients treated for infective endocarditis (IE) at our hospital between December 2016 and June 2023. To analyze short-term outcomes, the patients were divided into two groups based on whether they experienced poor outcomes. We compared demographic characteristics, echocardiographic findings, laboratory test results, surgical details, and postoperative outcomes between the two groups. Patients' long-term outcomes, including survival status and time of death, were assessed through follow-up, which involved telephone contact with the patient or their family. The follow-up period concluded on June 30, 2024. &lt;i&gt;Results.&lt;/i&gt; The median age of the patients was 55 years, with most patients ranging from 42 to 64 years. Male patients accounted for 67.1%, and 21.4% had underlying cardiac conditions. During hospitalization, 125 out of 210 patients (59.5%) underwent surgery, with an emergency surgery rate of 6.2% and an in-hospital mortality rate of 13.8%.Regarding short-term outcomes, multivariate logistic regression analysis indicated that surgical treatment (OR 0.211, 95% CI 0.073-0.621) was associated with better patient prognosis. Periannular abscess (OR 4.948, 95% CI 1.005-24.349) and poorer cardiac function (NYHA II [OR 0.041, 95% CI 0.008-0.224], NYHA III [HR 0.207, 95% CI 0.057-0.757], with NYHA IV as the reference group) were significantly associated with poor prognosis in IE patients. For long-term outcomes, multivariate Cox survival analysis showed that surgical treatment (HR 0.200, 95% CI 0.091-0.437) was associated with improved long-term survival. Cerebral infarction (HR 1.939, 95% CI 1.050-3.582) and poorer cardiac function (NYHA II [HR 0.108, 95% CI 0.037-0.313], NYHA III [HR 0.308, 95% CI 0.118-0.805], with NYHA IV as the reference group) were significant factors associated with long-term mortality in IE patients. &lt;i&gt;Conclusions.&lt;/i&gt; Surgical treatment was associated with improved short-term prognosis and long-term survival rates in patients with infective endocarditis. In terms of short-term outcomes, the presence of periannular abscesses and poor cardiac function were significant factor","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"59 1","pages":"2429994"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of colchicine compared to placebo for preventing ischemic stroke among individuals with established atherosclerotic cardiovascular diseases: a systematic review and meta-analysis.","authors":"Shulai Zhu, Weiwei Pan, Yingjie Yao, Kai Shi","doi":"10.1080/14017431.2024.2441112","DOIUrl":"10.1080/14017431.2024.2441112","url":null,"abstract":"<p><p><i>Background.</i> Colchicine is an anti-inflammatory drug with promising efficacy for preventing cardiovascular events. We aimed to assess the pooled effect of colchicine on ischemic stroke among patients with established atherosclerotic cardiovascular diseases. <i>Methods</i>. PubMed, Scopus, Web of Science, and the Cochrane Library were systematically searched from the inception to August 5, 2024. A random-effects (DerSimonian-Laird) model was used to conduct this meta-analysis. The inclusion criteria were as follows: (I) being a randomized controlled trial; and (II) measuring the efficacy of colchicine compared to placebo for preventing ischemic stroke among those with established atherosclerotic cardiovascular diseases. <i>Results</i>. We identified 13 eligible clinical trials with 24900 participants. Colchicine significantly decreased the risk of ischemic stroke (relative risk (RR) 0.85, 95% confidence interval (CI) (0.72, 0.99), I²=2.92%) among those with established atherosclerotic cardiovascular diseases. Colchicine was more effective when used at 0.5 mg/day (RR 0.86, 95% CI (0.75, 0.99)), prescribed for more than 30 days (RR 0.86, 95% CI (0.75, 1.00)) or for more than 90 days (RR 0.65, 95% CI (0.46, 0.92)), or administered for patients with acute coronary syndrome (RR 0.46, 95% CI (0.23, 0.92)). In addition, colchicine was more effective in studies with a sample size of more than 500 patients, consistent with sensitivity analysis, which indicated that the results relied on large-sized clinical trials. <i>Conclusion</i>. Colchicine may decrease the risk of ischemic stroke among patients with established atherosclerotic cardiovascular diseases, particularly after long-term use; however, future studies are needed due to inconsistencies between existing trials.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":" ","pages":"2441112"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of COVID-19 on cardiovascular function and exercise tolerance in healthy middle-age and older individuals.","authors":"Sophie L Russell, Nduka C Okwose, Mushidur Rahman, Ben J Lee, Gordon McGregor, Stuart M Raleigh, Hardip Sandhu, Laura C Roden, Prithwish Banerjee, Djordje G Jakovljevic","doi":"10.1080/14017431.2025.2468339","DOIUrl":"10.1080/14017431.2025.2468339","url":null,"abstract":"<p><strong>Aims: </strong>Coronavirus disease (COVID-19) can affect cardiovascular function in health and disease. The present study assessed the effect of prior COVID-19 infection on cardiovascular phenotype at rest and in response to exercise in middle age and older individuals.</p><p><strong>Methods: </strong>This case-control, single-centre study recruited 124 participants: 84 with a history of COVID-19 (59.9 ± 7.41 years, 54.8% female) and 40 participants without history of COVID-19 infection (62.8 ± 7.14 years, 62.5% female). All participants underwent non-invasive assessment of arterial function using pulse wave velocity (PWV), augmentation index (Alx) and hemodynamic function (i.e. cardiac index (CI), stroke volume index (SVI), heart rate (HR), mean arterial blood pressure (MAP)) at rest. Cardiopulmonary exercise stress testing with simultaneous gas exchange and hemodynamic (bioreactance) measurements was also performed.</p><p><strong>Results: </strong>There were no differences between COVID-19 and non-COVID-19 groups in PWV (COVID-19: 7.52 ± 1.66 m/s, non-COVID-19: 7.32 ± 1.79 m/s, <i>p</i> = 0.440); Alx (COVID-19: 29.2 ± 9.12%, non-COVID-19: 29.2 ± 8.44%, <i>p</i> = 0.980); CI (COVID-19: 2.85 ± 0.39 L/min/m², non-COVID-19: 2.79 ± 0.37 L/min/m², <i>p</i> = 0.407); SVI (COVID-19: 46.5 ± 7.54 mL/m², non-COVID-19: 47.0 ± 7.59 mL/m², <i>p</i> = 0.776), HR (COVID-19: 62.3 ± 10.6 beats/min, Non-COVID-19: 60.2 ± 8.52 beats/min, <i>p</i> = 0.263), or MAP (COVID-19: 98.1 ± 11.2 mmHg, non-COVID-19: 96.6 ± 9.46 mmHg, <i>p</i> = 0.464). COVID-19 participants however demonstrated lower O₂ consumption at anaerobic threshold (15.5 ± 4.25 vs 16.8 ± 4.51 mL/kg/m², <i>p</i> = 0.034), peak cardiac index (10.4 ± 2.3 vs 11.3 ± 2.5 L/min/m², <i>p</i> = 0.040) and peak stroke volume index (82.1 ± 25.3 vs 98.6 ± 37.6 mL/m², <i>p</i> = 0.028).</p><p><strong>Conclusion: </strong>Healthy middle-age and older individuals with history COVID-19 infection demonstrate reduced exercise tolerance and cardiac function response to exercise.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":" ","pages":"2468339"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiogenic shock and extracorporeal membrane oxygenation: Etiology and 1-year survival.","authors":"Inga L Ingvarsdottir, Andreas Westerlind, Isabella Lepore, Tomas Gudbjartsson, Bengt Redfors, Göran Dellgren","doi":"10.1080/14017431.2025.2481179","DOIUrl":"https://doi.org/10.1080/14017431.2025.2481179","url":null,"abstract":"<p><strong>Objectives: </strong>Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is used to provide cardiorespiratory support in cardiogenic shock, but selection of patients and timing of ECMO-start remains a challenge. This study aims to describe the 1 year outcome of VA-ECMO for cardiogenic shock with focus on etiology and severity of shock.</p><p><strong>Methods: </strong>VA-ECMO was used on 371 occasions between 2004 and 2019 at our centre. Of these, 177 patients received VA-ECMO for cardiogenic shock and were included in this retrospective single-center study. Univariable and multivariable logistic regression models were used to determine risk factors for all-cause mortality at 1 year.</p><p><strong>Results: </strong>Patients were grouped according to etiology: non-ishcemic heart failure (NIHF, N = 49), ischemic heart disease (IHD, N = 83) and miscellaneous diagnoses (Misc, N = 45). Markers of disease severity were lower for patients with NIHF. One year survival was 40% for all patients, 57%, 36% and 27% for the NIHF-, IHD and Misc-groups, respectively (p < 0.01). Univariable logistic regression analysis identified several variables associated with 1-year mortality, such as etiology, pH and lactate, while biventricular failure was associated with a better prognosis. However, in the multivariable analysis only ECPR remained significantly associated with increased mortality (OR 3.67, (CI 1.66-8.31), p <0.01).</p><p><strong>Conclusion: </strong>In this retrospective study of VA-ECMO for cardiogenic shock, we found an acceptable one-year survival rate of 40%, with a more favorable outcome for NIHF-patients. The negative association of ECPR with a higher 1 year mortality suggests the importance of patient selection as well as timing of the VA-ECMO before deterioration to cardiac arrest.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":" ","pages":"1-12"},"PeriodicalIF":1.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}